Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
2014 ◽
Vol 32
(15_suppl)
◽
pp. TPS3662-TPS3662
Keyword(s):
Phase Ii
◽